Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dihydralazine→

Dihydralazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
484-23-1
Molecular formula
C8H10N6
Molecular weight
190.21 g/mol
Drug class
Direct-acting arteriolar vasodilatorhydrazinophthalazine antihypertensive
Mechanism of action
Relaxes arteriolar vascular smooth muscle through effects on intracellular calcium handling and vascular signalling, reducing systemic vascular resistance and arterial blood pressure.
Indications / reported uses
  • Treatment of hypertension in countries where dihydralazine products remain authorised, including selected severe hypertension or pregnancy-related hypertension settings under specialist supervision; availability and indications are jurisdiction-specific

Sources: NLM MeSH — Dihydralazine · PubMed — Dihydralazine antihypertensive pharmacology · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Direct-acting arteriolar vasodilator; hydrazinophthalazine antihypertensive

Mechanism of action

Relaxes arteriolar vascular smooth muscle through effects on intracellular calcium handling and vascular signalling, reducing systemic vascular resistance and arterial blood pressure.

General use cases

  • Treatment of hypertension in countries where dihydralazine products remain authorised, including selected severe hypertension or pregnancy-related hypertension settings under specialist supervision; availability and indications are jurisdiction-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Dihydralazine Environmental Risk Assessment (ERA) (the Dihydralazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.